Cronos Group Competitors

Trillium Therapeutics (TSE:TRIL) and Cronos Group (TSE:CRON) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Profitability

This table compares Trillium Therapeutics and Cronos Group's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Trillium Therapeutics and Cronos Group, as provided by MarketBeat.com.

Trillium Therapeutics currently has a consensus price target of C$25.00, suggesting a potential upside of 91.42%. Cronos Group has a consensus price target of C$9.68, suggesting a potential downside of 12.87%. Given Trillium Therapeutics' higher possible upside, research analysts plainly believe Trillium Therapeutics is more favorable than Cronos Group.

Valuation & Earnings

This table compares Trillium Therapeutics and Cronos Group's revenue, earnings per share and valuation.

Cronos Group has higher revenue and earnings than Trillium Therapeutics. Cronos Group is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Cronos Group beats Trillium Therapeutics on 4 of the 7 factors compared between the two stocks.

Concordia International (TSE:CXR) and Cronos Group (TSE:CRON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Concordia International and Cronos Group's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Concordia International and Cronos Group, as provided by MarketBeat.

Cronos Group has a consensus price target of C$9.68, suggesting a potential downside of 12.87%.

Earnings and Valuation

This table compares Concordia International and Cronos Group's revenue, earnings per share and valuation.

Concordia International has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Summary

Concordia International beats Cronos Group on 4 of the 5 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and Cronos Group (TSE:CRON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Aptose Biosciences and Cronos Group's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Aptose Biosciences and Cronos Group, as provided by MarketBeat.

Aptose Biosciences currently has a consensus price target of C$12.00, suggesting a potential upside of 81.54%. Cronos Group has a consensus price target of C$9.68, suggesting a potential downside of 12.87%. Given Aptose Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Aptose Biosciences is more favorable than Cronos Group.

Earnings and Valuation

This table compares Aptose Biosciences and Cronos Group's revenue, earnings per share and valuation.

Aptose Biosciences has higher earnings, but lower revenue than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Aptose Biosciences beats Cronos Group on 3 of the 5 factors compared between the two stocks.

Burcon NutraScience (TSE:BU) and Cronos Group (TSE:CRON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Burcon NutraScience and Cronos Group's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Burcon NutraScience and Cronos Group, as provided by MarketBeat.

Burcon NutraScience currently has a consensus price target of C$5.00, suggesting a potential downside of 7.75%. Cronos Group has a consensus price target of C$9.68, suggesting a potential downside of 12.87%. Given Burcon NutraScience's stronger consensus rating and higher possible upside, equities analysts plainly believe Burcon NutraScience is more favorable than Cronos Group.

Earnings and Valuation

This table compares Burcon NutraScience and Cronos Group's revenue, earnings per share and valuation.

Burcon NutraScience has higher earnings, but lower revenue than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience beats Cronos Group on 6 of the 8 factors compared between the two stocks.

Theratechnologies (TSE:TH) and Cronos Group (TSE:CRON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Theratechnologies and Cronos Group's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Theratechnologies and Cronos Group, as provided by MarketBeat.

Theratechnologies currently has a consensus price target of C$3.75, suggesting a potential downside of 21.38%. Cronos Group has a consensus price target of C$9.68, suggesting a potential downside of 12.87%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts plainly believe Cronos Group is more favorable than Theratechnologies.

Earnings and Valuation

This table compares Theratechnologies and Cronos Group's revenue, earnings per share and valuation.

Theratechnologies has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Summary

Cronos Group beats Theratechnologies on 5 of the 8 factors compared between the two stocks.

Cronos Group (TSE:CRON) and BELLUS Health (TSE:BLU) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Earnings & Valuation

This table compares Cronos Group and BELLUS Health's revenue, earnings per share (EPS) and valuation.

BELLUS Health has lower revenue, but higher earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Cronos Group and BELLUS Health, as provided by MarketBeat.

Cronos Group presently has a consensus price target of C$9.68, suggesting a potential downside of 12.87%. Given Cronos Group's higher possible upside, research analysts clearly believe Cronos Group is more favorable than BELLUS Health.

Profitability

This table compares Cronos Group and BELLUS Health's net margins, return on equity and return on assets.